Source: Medical Xpress
A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in an international clinical trial of more than 200 patients worldwide. Results from the trial showed that patients with psoriatic arthritis who were treated with a new nanobody drug called sonelokimab, achieved much greater improvements in joint pain, swelling, and skin symptoms than patients who received a placebo.
